Afficher la notice abrégée

dc.contributor.authorRoma Rodrigues, Catarina
dc.contributor.authorRivas-García, Lorenzo
dc.contributor.authorBaptista, Pedro V.
dc.contributor.authorFernandes, Alexandra R.
dc.date.accessioned2020-05-12T11:51:00Z
dc.date.available2020-05-12T11:51:00Z
dc.date.issued2020-03-05
dc.identifier.citationRoma-Rodrigues, C., Rivas-García, L., Baptista, P. V., & Fernandes, A. R. (2020). Gene Therapy in Cancer Treatment: Why Go Nano?. Pharmaceutics, 12(3), 233.es_ES
dc.identifier.urihttp://hdl.handle.net/10481/61996
dc.description.abstractThe proposal of gene therapy to tackle cancer development has been instrumental for the development of novel approaches and strategies to fight this disease, but the efficacy of the proposed strategies has still fallen short of delivering the full potential of gene therapy in the clinic. Despite the plethora of gene modulation approaches, e.g., gene silencing, antisense therapy, RNA interference, gene and genome editing, finding a way to efficiently deliver these effectors to the desired cell and tissue has been a challenge. Nanomedicine has put forward several innovative platforms to overcome this obstacle. Most of these platforms rely on the application of nanoscale structures, with particular focus on nanoparticles. Herein, we review the current trends on the use of nanoparticles designed for cancer gene therapy, including inorganic, organic, or biological (e.g., exosomes) variants, in clinical development and their progress towards clinical applications.es_ES
dc.description.sponsorshipThis work was supported by the Applied Molecular Biosciences Unit - UCIBIO which is financed by national funds from FCT (UIDB/04378/2020), CRR (SFRH/BPD/124612/2016) and LRG (Inn-Indigo 00002/2015 RA Detect).es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectGene therapy es_ES
dc.subjectGene deliveryes_ES
dc.subjectTumor Microenvironmentes_ES
dc.subjectNanoparticleses_ES
dc.subjectNanomedicinees_ES
dc.titleGene Therapy in Cancer Treatment: Why Go Nano?es_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/pharmaceutics12030233


Fichier(s) constituant ce document

[PDF]

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Atribución 3.0 España
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Atribución 3.0 España